blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3941947

EP3941947 - ANTI-HER2 BINDING MOLECULES [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  24.12.2021
Database last updated on 02.11.2024
FormerThe international publication has been made
Status updated on  03.10.2020
Most recent event   Tooltip12.04.2024Change - applicantpublished on 15.05.2024  [2024/20]
Applicant(s)For all designated states
Certis Therapeutics Pty Ltd
37 Munro Street
Kew East, Victoria 3102 / AU
[2024/20]
Former [2022/04]For all designated states
Olivia Newton-John Cancer Research Institute
Level 5 ONJ Centre
145 Studley Raod
Heidelberg, Victoria 3084 / AU
Inventor(s)01 / SCOTT, Andrew Mark
C/- Olivia Newton-John Cancer Research Institute
Level 5, ONJ Centre
145 Studley Road
Heidelberg, Victoria 3084 / AU
02 / GAN, Hui Kong
C/- Olivia Newton-John Cancer Research Institute
Level 5, ONJ Centre
145 Studley Road
Heidelberg, Victoria 3084 / AU
03 / LIU, Zhanqi
C/- Olivia Newton-John Cancer Research Institute
Level 5, ONJ Centre
145 Studley Road
Heidelberg, Victoria 3084 / AU
04 / PARAKH, Sagun
C/- Olivia Newton-John Cancer Research Institute
Level 5, ONJ Centre
145 Studley Road
Heidelberg, Victoria 3084 / AU
[N/P]
Former [2022/04]01 / SCOTT, Andrew Mark
Heidelberg, Victoria 3084 / AU
02 / GAN, Hui Kong
Heidelberg, Victoria 3084 / AU
03 / LIU, Zhanqi
Heidelberg, Victoria 3084 / AU
04 / PARAKH, Sagun
Heidelberg, Victoria 3084 / AU
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2022/04]
Application number, filing date20779333.220.03.2020
[2022/04]
WO2020AU50274
Priority number, dateAU2019090097322.03.2019         Original published format: AU 2019900973
[2022/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020191434
Date:01.10.2020
Language:EN
[2020/40]
Type: A1 Application with search report 
No.:EP3941947
Date:26.01.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 01.10.2020 takes the place of the publication of the European patent application.
[2022/04]
Search report(s)International search report - published on:AU01.10.2020
(Supplementary) European search report - dispatched on:EP16.11.2022
ClassificationIPC:C07K16/30, A61K39/395, A61P35/00
[2022/04]
CPC:
A61P35/00 (EP,AU,US); C07K16/32 (EP,AU,US); G01N33/566 (EP);
G01N33/57484 (AU,US); A61K2039/505 (EP,AU,US); A61K2039/507 (EP);
A61K2121/00 (AU); C07K2317/34 (EP,US); C07K2317/73 (EP,US);
C07K2317/92 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/04]
TitleGerman:ANTI-HER2-BINDUNGSMOLEKÜLE[2022/04]
English:ANTI-HER2 BINDING MOLECULES[2022/04]
French:MOLÉCULES DE LIAISON ANTI-HER2[2022/04]
Entry into regional phase20.10.2021National basic fee paid 
20.10.2021Search fee paid 
20.10.2021Designation fee(s) paid 
20.10.2021Examination fee paid 
Examination procedure20.10.2021Examination requested  [2022/04]
07.07.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
14.09.2023Amendment by applicant (claims and/or description)
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
14.09.2023Request for further processing filed
14.09.2023Full payment received (date of receipt of payment)
Request granted
25.09.2023Decision despatched
Fees paidRenewal fee
20.10.2021Renewal fee patent year 03
23.02.2023Renewal fee patent year 04
01.03.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]WO9817797  (GENENTECH INC [US], et al) [I] 1-15 * page 38, line 23 - line 25; examples 1,4; claim 1 * * page 41, paragraph l *;
 [X]WO2006138675  (UNIV OHIO STATE RES FOUND [US], et al) [X] 1,2 * page 11, paragraph 2; claims 30,1,11; sequences 7,24,25 *;
 [X]WO2009023266  (LUDWIG INST CANCER RES [US], et al) [X] 1,2 * paragraphs [0180] , [0081]; example 2 *;
 [I]WO2011107957  (SYMPHOGEN AS [DK], et al) [I] 3-15 * the whole document * * examples 3,4; claim 5; table 8; sequence 40 *;
 [I]EP3115377  (GENOR BIOPHARMA CO LTD [CN]) [I] 1-15 * examples 1,12-14; table 3 *;
 [I]WO2017191327  (MAB DISCOVERY GMBH [DE]) [I] 1-15 * the whole document ** figures 3,4,12-15 *;
 [I]  - AMIRI MOHAMMAD MEHDI ET AL, "Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition", INVESTIGATIONAL NEW DRUGS, SPRINGER US, NEW YORK, vol. 36, no. 2, doi:10.1007/S10637-017-0518-0, ISSN 0167-6997, (20171006), pages 171 - 186, (20171006), XP036466711 [I] 1-15 * abstract * * page 172, column l, paragraph 2 * * page 178, column r * * page 179, column r *

DOI:   http://dx.doi.org/10.1007/s10637-017-0518-0
 [I]  - TOHID KAZEMI ET AL, "Characterization of Novel Murine Monoclonal Antibodies Directed Against the Extracellular Domain of Human HER2 Tyrosine Kinase Receptor", HYBRIDOMA, US, (20110801), vol. 30, no. 4, doi:10.1089/hyb.2011.0023, ISSN 1554-0014, pages 347 - 353, XP055706329 [I] 1-15 * page 349, column r, paragraph 3 - paragraph 4; table 1 *

DOI:   http://dx.doi.org/10.1089/hyb.2011.0023
International search[X]WO2005081854  (LUDWIG INST CANCER RES [US], et al) [X] 1, 2 and 13-20 * (D1: see abstract, page 28 lines 20-26, page 37 line 29 - page 39 line 20, page 47 line 11 - page 48 line 26, claims 9, 18, 27-32 and SEQ ID NO. 8) *;
 [A]WO2006138675  (UNIV OHIO STATE RES FOUND [US], et al) [A] 1-20* (D5 see abstract, Example 7 and claims). *;
 [X]WO2008033495  (LIFE SCIENCE PHARMACEUTICALS [US], et al) [X] 1, 2 and 13-18 * (D3: see paragraphs [0033]-[0034],[0071]-[0072] and claims). *;
 [X]WO2009023266  (LUDWIG INST CANCER RES [US], et al) [X] 1, 2 and 13-20 * (D2: see abstract, paragraphs [0012]-[0014], [0043]-[0048], Example 3, claims and SEQ ID NO. 3) *;
 [A]WO2014131019  (OHIO STATE INNOVATION FOUNDATION [US]) [A] 1-20 * (D4: see paragraphs [074]-[075], Table 5, claim 14). *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.